Tricuspid Regurgitation

Normal path
of blood flow


What is Tricuspid Regurgitation?

Tricuspid regurgitation (TR) is a disorder in which the heart’s tricuspid valve does not close properly, causing blood to flow backward (leak) into the right upper heart chamber (atrium) when the right lower heart chamber (ventricle) contracts, reducing its efficiency. Severe TR affects more than 1.6 million patients in the U.S. today.

The onset of tricuspid regurgitation may be due to a structural change of components of the tricuspid valve apparatus, a lesion can be primary (intrinsic abnormality) or secondary/functional (right ventricular dilatation).

What are Symptoms of Tricuspid Regurgitation?

Tricuspid regurgitation may not cause any symptoms if the regurgitation is not severe. However, patients may experience:

  • Active pulsing in the neck veins
  • Decreased urine output
  • Fatigue, tiredness
  • General swelling
  • Swelling of the abdomen
  • Swelling of the feet and ankles
  • Weakness

Treatment Options for Tricuspid Regurgitation

  • Surgical Valve Repair – Your surgeon may perform valve repair by separating tethered valve leaflets, by closing holes (fenestrations) in leaflets and by reshaping the valve leaflets so that they can make contact with each other and prevent backward flow.
  • Surgical Valve Replacement – If your tricuspid valve cannot be repaired, your surgeon may replace it with a biological or mechanical valve. In tricuspid valve replacement, your surgeon replaces the valve by removing part of the deformed valve and inserting a biological tissue (bioprosthetic) valve.
  • Medical Management – For patients who are at high risk for surgery, the standard of care to treat TR is medical management. Unfortunately, this treatment option is ineffective and may result in complications that can lead to multiple re-hospitalizations. There is a significant unmet clinical need for a percutaneous solution to treat TR.

An unmet clinical need

significant health care spending is induce by FTR due to frequent re-hospitalizations and end-stage dialysis.
All major cardiovascular medtech corporations are looking for technologies to complete their Structural Heart Disease treatment portfolios.
About 1.6 million patients in the U.S are affected by the FTR
FTR is secondary to Functional Mitral Regurgitation (FMR), in the majority of patients.
Patients are in the chain of care, followed-up in Chronic Heart Failure clinics.
Interventional cardiologists are looking for solutions to treat FTR.
Very high risk regarding surgery for FTR
Standard of care is medication, mostly diuretics.
Tricinch™ Transcatheter Tricuspid Valve Repair (TTVR) System

A four-step procedure for Transcatheter Tricuspid Valve Repair (TTVR) The 4Tech TriCinch™ System is designed to provide a simple and effective 4-step procedure aiming to reduce functional TR by reducing the septo-lateral (SL) distance: Access Right Atrium via Inferior Vena Cava and place anchor onto Tricuspid valve annulus. Withdraw first delivery system, advance a second delivery